跳至主要内容
临床试验/KCT0007225
KCT0007225
尚未招募
未知

A 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Panax ginseng C.A. Meyer sprout extract on improvement of Memory Function

Woosuk University Korean Medicine Medical Center0 个研究点目标入组 80 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Symptoms, signs and abnormal clinical and laboratory findings, NEC
发起方
Woosuk University Korean Medicine Medical Center
入组人数
80
状态
尚未招募
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
4年前
研究类型
Interventional Study
性别
All

研究者

发起方
Woosuk University Korean Medicine Medical Center

入排标准

入选标准

  • 1\) Males and females aged 55\-75 years at the screening examination
  • 2\) Those who complain of subjective memory loss {one or more points in the subjective memory loss questionnaire (SMCQ)}
  • 3\) A person whose age and educational background standard deviation have been reduced by more than one of the three items (free recall, delayed recall, and re\-insurance test) of the Seoul Language Learning Test (SVLT) or Ray Complex Figure Test (RCFT), which is a memory test
  • 4\) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions.

排除标准

  • 1\)Patients with a clinically significant disease requiring treatment (i.e., acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.)
  • 2\)Patients with a history of antipsychotic medication use within 3 months prior to the screening examination
  • 3\)Patients with a history of clinically significant hypersensitivity reactions to drugs and test products
  • 4\)Patients who have participated in other clinical trials within 3 months prior to the screening examination
  • 5\)Patients with a Severe score of 29\-63 points as a result of the Depression Scale (BDI) test
  • 6\)Patients who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes

结局指标

主要结局

未指定

相似试验